Trial Profile
Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)(WS)(ISNHP)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Stannsoporfin (Primary)
- Indications Hyperbilirubinaemia
- Focus Adverse reactions
- Sponsors InfaCare Pharmaceutical Corporation
- 17 Jul 2017 Status changed from active, no longer recruiting to discontinued because of business reasons.
- 23 Feb 2016 New trial record